Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma

NCT00073957 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma

Interventions

BIOLOGICAL: rituximab
DRUG: cytarabine
DRUG: liposomal cytarabine
RADIATION: yttrium Y 90 ibritumomab tiuxetan

Sponsor

Beth Israel Deaconess Medical Center